Phase 1 Study of Dimethandrolone Undecanoate in Healthy Men

Healthy Men Clinical Trial

— DMAUPhase1  

Official title:

Single Dose, Dose-Ranging and 28-Day Repeat-Dose Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Dimethandrolone Undecanoate (DMAU) in Healthy Men

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01382069
• Other study ID #: CCN010
• Secondary ID: HHSN275201000080
• Status: Completed
• Phase: Phase 1
• First received: March 25, 2011
• Last updated: June 29, 2017
• Start date: March 2012
• Est. completion date: May 2017

Study information

• Verified date: July 2016
• Source: Los Angeles Biomedical Research Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The long term objective is to develop a new male hormone Dimethandrolone Undecanoate (DMAU) as a male hormonal contraceptive.

The study has two parts. The first is a dose escalating study in healthy to assess the safety and tolerability of single dose oral administration of DMAUin healthy men.(Completed)

The second is to study the safety and tolerability of DMAU after 28 days of repeated daily dosing of DMAU in healthy men. (Currently Recruiting) In both parts the investigators will also study the pharmacokinetics of Dimethandrolone (DMA) in the serum after oral administration of DMAU.

Description:

The study will be conducted in two centers.

28-Day Repeat-Dose, Dose-Escalation Study: Based on the safety and tolerability of the single dose study and serum DMA levels attained, three doses of two formulations of DMAU were selected for a dose-escalating 28-day repeat dose study. Safety will be assessed in subjects receiving lower dosages before additional men receive higher doses for 28 days. Up to 100 men will be randomized to receive either active drug or an identical number of capsules of placebo. The 24-hour detailed PK of DMA will be assessed on day 1 and 28. Trough levels of DMA will be obtained throughout the 28-day period and at 48 and 72 hours after the last dose. In addition to safety and tolerability, suppression of serum T, gonadotropins, and SHBG will also be assessed as secondary pharmacodynamic (PD) endpoints. Psychosexual diaries for 7 consecutive days and PHQ-9 (questionnaire)will be obtained before and at the end of the study period.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 100
• Est. completion date: May 2017
• Est. primary completion date: February 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

1. Male volunteers in good health as confirmed by physical examination, medical history, and clinical laboratory tests of blood and urine at the time of screening.

2. 18 to 50 years of age.

3. BMI < 33 calculated as weight in kg/ (height in m2 )

4. No history of hormonal therapy use in the last three months prior to the first screening visit.

5. Subject will agree to use a recognized effective method of contraception with his partner (i.e. at a minimum, use double-barrier contraception) during the course of the study treatment and recovery phase.

6. Subjects will refrain from donating blood or plasma during the study period.

7. Subjects will be advised to refrain/abstain from alcoholic beverages and grapefruit juice during the study period.

8. Subjects will not use cannabis or any recreational drugs at least 4 weeks before screening and during the study.

9. In the opinion of the investigator, subject is able to comply with the protocol, understand and sign an informed consent and HIPAA form.

10. Does not meet any of the exclusion criteria.

Exclusion Criteria:

1. Men participating in another clinical trial involving an investigational drug within the last 30 days prior to the first screening visit.

2. Men not living in the catchment's area of the clinic or within a reasonable distance from the study site.

3. Clinically significant abnormal physical and laboratory findings at screening.

4. Elevated PSA (levels = 2.5 ng/mL), according to local laboratory normal values.

5. Abnormal serum chemistry values, according to local laboratory reference ranges that indicate liver or kidney dysfunction or that may be considered clinically significant except for: an upper limit for fasting bilirubin is less than 2 mg/dL, upper limit for cholesterol is less than 220 mg/dL, or upper limit for fasting triglycerides is less than 200 mg/dL.

6. Abnormal semen analyses or abnormal semen concentration as defined by the WHO semen manual.

7. Use of androgens or other body building substances including nutritional supplements within 3 months before first screening visit.

8. Systolic BP > 130 mm Hg and Diastolic blood pressure BP > 80 and mm Hg; ((BP) Blood pressure will be taken 3 times at 5-minute intervals and the mean of all measurements be considered).

9. Clinically significant abnormal EKG and a QTc interval of > 450 msec.

10. PHQ-9 score of 15 or above [for the 28 days study].

11. History of hypertension, including hypertension controlled with treatment.

12. Known history of primary testicular disease or disorders of the hypothalamic-pituitary axis.

13. Benign or malignant liver tumors; active liver disease.

14. History of breast carcinoma.

15. Known history of androgen deficiency due to hypothalamic-pituitary or testicular disease.

16. Known history of cardiac, renal, hepatic or prostatic disease.

17. Positive serology for Hepatitis or HIV at screening visit.

18. A serious systemic disease such as diabetes mellitus or obesity (body weight greater than BMI >33 kg/m2 as above).

19. History of known, untreated sleep apnea.

20. Known or suspected alcoholism or drug abuse that may affect metabolism/transformation of steroid hormones and study treatment compliance.

21. Partner is known to be pregnant.

22. Men desiring fertility within the first 24 weeks of study participation.

23. Men participating in competitive sports where drug screening for prohibited substances (including anabolic steroids) is routine will be advised of the relative and temporary hazards that participating in this study may have for their fertility or sporting status.

Related Conditions & MeSH terms

• Healthy Men
• Male Contraception

Intervention

Drug:
• Dimethandrolone Undecanoate
Daily doses of 100, 200 and 400mg of dimethandrolone undecanoate
• Placebo
Placebo with capsules that look like the DMAU capsules but with no active ingredients

Locations

Country	Name	City	State
United States	University of Washington	Seattle	Washington
United States	Los Angeles Biomedical Research Institute	Torrance	California

Sponsors (3)

Lead Sponsor	Collaborator
Los Angeles Biomedical Research Institute	National Institutes of Health (NIH), University of Washington

Country where clinical trial is conducted

United States, 

References & Publications (3)

Attardi BJ, Engbring JA, Gropp D, Hild SA. Development of dimethandrolone 17beta-undecanoate (DMAU) as an oral male hormonal contraceptive: induction of infertility and recovery of fertility in adult male rabbits. J Androl. 2011 Sep-Oct;32(5):530-40. doi: 10.2164/jandrol.110.011817. Epub 2010 Dec 16. — View Citation

Attardi BJ, Hild SA, Reel JR. Dimethandrolone undecanoate: a new potent orally active androgen with progestational activity. Endocrinology. 2006 Jun;147(6):3016-26. Epub 2006 Feb 23. — View Citation

Attardi BJ, Marck BT, Matsumoto AM, Koduri S, Hild SA. Long-term effects of dimethandrolone 17ß-undecanoate and 11ß-methyl-19-nortestosterone 17ß-dodecylcarbonate on body composition, bone mineral density, serum gonadotropins, and androgenic/anabolic activity in castrated male rats. J Androl. 2011 Mar-Apr;32(2):183-92. doi: 10.2164/jandrol.110.010371. Epub 2010 Aug 26. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Single Dose, Dose-Ranging and 28-Day Repeat-Dose Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Dimethandrolone Undecanoate (DMAU) in Healthy Men	Number of severe or serious adverse event fdter escalating single doses of Dimethandrolone Undecanoated in a single dose escalating study or after 28 days repeat dosing in healthy men	1 day
Secondary	Single Dose, Dose-Ranging and 28 days Repeat Dose Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Dimethandrolone Undecanoate (DMAU) in Healthy Men	Serum Dimethandrolone Levels on day 28	28 days
Secondary	Single Dose, Dose-Ranging and 28-Day Repeat-Dose Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Dimethandrolone Undecanoate (DMAU) in Healthy Men	Serum Dimethandrolone levels	2 days Food or no food
Secondary	Single Dose, Dose-Ranging and 28-Day Repeat-Dose Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Dimethandrolone Undecanoate (DMAU) in Healthy Men	Serum hormone levels (Testosterone (T), FSH and LH and SHBG) and sexual function.	28 DAYS